http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-587420-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_555896a2f43ea629dbc0f99b94cfd297 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2009-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b9bf2fc9585537071096cdfd0dee641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60749d764e406a3e0062a4ca26335d58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9585e7103f4ac05f3d617aa3dbd55322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68b6bb231c8392f702f552e9a8c3990d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06cb4b0ab3877f9a2d6775644faf5f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef094c8379d6faca75945273ec3f1a03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ea70b829b760931c98e3617ff1ddec2 |
| publicationDate | 2012-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-587420-A |
| titleOfInvention | Drug selection for breast cancer therapy using antibody-based arrays |
| abstract | method for selecting a suitable anticancer d 1 rug for the treatment of a breast tumor, the method comprising: (a) lysing cells of a breast tumor isolated after administration of an anticancer drug, or prior to incubation with an anticancer drug to produce a cellular extract; (b) detecting an activation state of one or more analytes in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the one or more analytes, wherein the capture antibodies are restrained on a solid support; and wherein the assay comprises: (i) incubating the cellular extract with the plurality of dilution series of capture antibodies to form a plurality of captured analytes; (ii) incubating the plurality of captured analytes with detection antibodies comprising a plurality of activation state-independent antibodies and a plurality of activation state-dependent antibodies specific for the corresponding analytes to form a plurality of detectable captured analytes, wherein the activation state-independent antibodies are labeled with glucose oxidase, wherein the glucose oxidase and the activation state20 independent antibodies are conjugated to a sulfhydryl-activated dextran molecule, wherein the activation state-dependent antibodies are labeled with a first member of a signal amplification pair, and wherein the glucose oxidase generates an oxidizing agent which channels to and reacts with the first member of the signal amplification pair; (iii) incubating the plurality of detectable captured analytes with a second member of the signal amplification pair to generate an amplified signal; and (iv) detecting the amplified signal generated from the first and second members of the signal amplification pair; and (c) determining whether the anticancer drug is suitable or unsuitable for the Provided is a method for selecting a suitable breast cancer drug or identifying a response to treatment by a breast cancer drug, the method comprising: (a) lysing cells of a breast tumor isolated after administration of an anticancer drug, or prior to incubation with an anticancer drug to produce a cellular extract; (b) detecting an activation state of one or more analytes in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the one or more analytes, wherein the capture antibodies are restrained on a solid support; and wherein the assay comprises: (i) incubating the cellular extract with the plurality of dilution series of capture antibodies to form a plurality of captured analytes; (ii) incubating the plurality of captured analytes with detection antibodies comprising a plurality of activation state-independent antibodies and a plurality of activation state-dependent antibodies specific for the corresponding analytes to form a plurality of detectable captured analytes, wherein the activation state-independent antibodies are labelled with glucose oxidase, wherein the glucose oxidase and the activation state independent antibodies are conjugated to a sulfhydryl-activated dextran molecule, wherein the activation state-dependent antibodies are labelled with a first member of a signal amplification pair, and wherein the glucose oxidase generates an oxidizing agent which channels to and reacts with the first member of the signal amplification pair; (iii) incubating the plurality of detectable captured analytes with a second member of the signal amplification pair to generate an amplified signal; and (iv) detecting the amplified signal generated from the first and second members of the signal amplification pair; and (c) determining whether the anticancer drug is suitable or unsuitable for the treatment of the breast tumor by comparing the activation state detected for the one or more analytes with a reference activation profile generated in the absence of the anticancer drug. |
| priorityDate | 2008-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1930.